Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2023 Earnings Presentation
17 slides from Aurobindo Pharma's earnings presentation, May 27, 2023
Slide 1: Letter to stock exchanges: Investor / Analysts Presentation
May 27, 2023 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI -400 051 25th floor, Dalal Street, MUMBAI -400 001 Company Code No. AUROPHARMA Company Cod
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q4FY23
Aurobindo Pharma Limited Earnings Presentation Q4FY23
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q4FY23 Business & Financial Highlights 10 Financial Performance 13 Filings Snapshot 3
Slide 5: Q4FY23 Business & Financial Highlights
Q4FY23 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q4 FY23
Quarterly Performance – Q4 FY23 Revenue (Rs Crore) US Revenue (US$ Mn) 386 6,407 6,473 367 363 366 370 6,236 6,002 5,809 5,739 331 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 EBITDA (Rs Crore) Net Debt to Equity* 1,016 974 965 954 1,002 837 -0.06 -0.06 -0.07 -
Slide 7: Consolidated Financial & Business Highlights – Q4 FY23
Consolidated Financial & Business Highlights – Q4 FY23 Revenue from operations at Rs 6,473.0 crore, an increase of 11.4% YoY, US revenues at US$ 370.4 Million Research & Development spend at Rs 410.7 crore in Q4FY23 (6.3% of revenue) Vs. Rs. 415.2 crore in Q3FY23 EBITDA before Forex and Other income
Slide 8: Consolidated Operational Performance
Consolidated Operational Performance % Change % Change % Change Amount (INR Cr) Q4FY23 Q4FY22 Q3FY23 FY23 FY22 YoY QoQ YoY Formulations USA 3,045 2,728 11.6% 3,001 1.4% 11,654 11,122 4.8% Europe 1,660 1,541 7.7% 1,701 -2.4% 6,426 6,480 -0.8% Growth Markets* 592 391 51.2% 499 18.6% 1,973 1,504 31.2%
Slide 9: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) US Formulations 3,001 3,045 • US revenue in Q4FY23 increased by 11.6% YoY and 1.4% 2,728 QoQ to Rs. 3,044.5 crores, accounting for 47.0% of consolidated revenue • Eugia revenue in the US which includes injectables & specialty OSD, was US$ 81.3 Mn
Slide 10: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights Europe (Rs Crore) Growth Markets (Rs Crore) ARV (Rs Crore) API (Rs Crore) 1017 1,701 1,660 591 955 1,541 499 913 391 236 251 159 Q4FY22 Q3FY23 Q4FY23 Q4FY22 Q3FY23 Q4FY23 Q4FY22 Q3FY23 Q4FY23 Q4FY22 Q3FY23 Q4FY23 Revenue fro
Slide 11: Financial Summary
Financial Summary 10
Slide 12: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q4FY23 Q4FY22 YoY Chg. (%) Q3FY23 QoQ Chg. (%) FY23 FY22 YoY Chg. (%) Revenue from operations 6,473.0 5,809.4 11.4% 6,407.1 1.0% 24,855.4 23,455.5 6.0% Gross Profit 3,542.0 3,285.2 7.8% 3,499.6 1.2% 13,562.1 13,315.2 1.9% Gross Margin 54.7% 56
Slide 13: Debt profile
Debt profile Forex Loan (US$ Mn) Debt as on (INR Cr) Mar-20 Mar-21 Mar-22 Dec-22 Mar-23 Closing Rate (INR/USD) 75.665 73.110 75.793 82.725 82.170 732 674 313 496 592 Fx Loan restated in INR 5,549 4,929 2,223 3,745 4,638 Rupee Loan 16.9 43.6 150.1 355.0 224.0 Gross Debt 5,566 4,972 2,373 4,100 4,862
Slide 14: Filing Status
Filing Status 13
Slide 15: US ANDA Filings Snapshot as on 31st March 2023
US ANDA Filings Snapshot as on 31st March 2023 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 140 26.7 Aurobindo (Excl. Eugia Pharma Eugia Pharma Specialty Group 600 565 417 148 ARV** 38 0.6 450 160 500 400 140 Specialty Group) 350 120 400 38.8 300 300 250 100 80 68 CVS 109 200 175
Slide 16: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Mar 23 US* 398 429 478 541 586 639 727 774 (FA: 565, TA:34) Europe** 2,224 2,521 2,848 3,003 3,214 3,374 3,580 3,751 3,116 Dossiers (372 prod
Slide 17: Thank You
Thank You For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 5401 16